Emcure FY26 Revenue Crosses $1 Billion, Up 16.6%

Emcure Pharmaceuticals reported FY26 revenue of INR9,204 crores, a 16.6% YoY growth, exceeding guidance and surpassing the $1 billion milestone.
Key growth drivers included a 22% surge in international markets and strategic in-licensing deals with Novo Nordisk, Sanofi, and Roche.
The company provided FY27 guidance for low-to-mid-teen revenue growth and 75-100 basis points of EBITDA margin expansion.
Q4 domestic growth was soft at 5.2% due to restructuring at recently consolidated subsidiary Zuventus, but management stated April performance is back on track.